News & Events

Clinical Trial: TCR1188-ABC Cells in KRAS-mutated Cancers

Clinical Trial: TCR1188-ABC Cells in KRAS-mutated Cancers

Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC

Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC

T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC

T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC

How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?

How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?

Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC

Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC

HMN 2026: How Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

HMN 2026: How Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Findings from Stanford University School of Medicine in the Area of Non-Small Cell Lung Cancer Reported (KRAS G12C inhibitor outcomes in advanced non-small cell lung...

Findings from Stanford University School of Medicine in the Area of Non-Small Cell Lung Cancer Reported (KRAS G12C inhibitor outcomes in advanced non-small cell lung...

Jacobio-Licensed KRAS G12C and SHP2 Inhibitor Combination Receives Breakthrough Therapy Designation in China

Jacobio-Licensed KRAS G12C and SHP2 Inhibitor Combination Receives Breakthrough Therapy Designation in China